Henry Ford Health System

Henry Ford Health System Scholarly Commons

Case Reports

Medical Education Research Forum 2020

5-2020

An Unusual Presentation of Recurrent Squamous Cell Carcinoma

Tasneem F. Mohammad

Henry Ford Health System, TMOHAMM2@hfhs.org

Aaron Tisack

Mark R. Balle
Henry Ford Health System, MBALLE1@hfhs.org

Joseph McGoey Henry Ford Health System, jmcgoey1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/merf2020caserpt

Recommended Citation

Mohammad, Tasneem F.; Tisack, Aaron; Balle, Mark R.; and McGoey, Joseph, "An Unusual Presentation of Recurrent Squamous Cell Carcinoma" (2020). *Case Reports*. 129. https://scholarlycommons.henryford.com/merf2020caserpt/129

This Poster is brought to you for free and open access by the Medical Education Research Forum 2020 at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Case Reports by an authorized administrator of Henry Ford Health System Scholarly Commons.



An Unusual Presentation of Recurrent Squamous Cell Carcinoma

Tasneem Mohammad MD, Aaron Tisack BS, Mark Balle MD, and Joseph McGoey MD

Department of Dermatology Henry Ford Health System, Detroit, MI



History

- A 65-year old African American male with a past medical history of untreated prostate cancer and anal cancer status post chemoradiation presented to dermatology due to a nonhealing wound on the lateral right hip.
- The patient had previously undergone excision of a cutaneous squamous cell carcinoma (cSCC) in this area, followed by Mohs surgery due to local recurrence.
- In both procedures, clear margins were noted histologically.
- The patient noted that although the area had healed partially, the center had not healed and he had begun to develop a painful rash with blisters surrounding the wound

Examination

- On the right hip there was a large non-healing wound with granulation tissue and yellow fibrinous adherent material.
- The posterior edge of the wound had grouped greyish papules and fluctuant vesicles with serosanguinous drainage.
- On subsequent visits the lesions were rapidly progressive.

Histopathology







Figure 1: Punch biopsy of the right hip shows epidermal hyperplasia and ulceration with atypical squamous islands invading into the dermis.

Clinical Photos



Figure 2: cSCC of the right hip prior to Mohs surgery.



Course and Therapy

- Due to the vesicular and rapidly spreading nature of the lesion, an infectious process was favored. However, there was no improvement after treatment with antibiotics and antivirals.
- At follow up, progression was noted. The differential at that time included recurrent SCC versus pyoderma gangrenosum versus infection.
- Biopsies for H&E and for tissue culture (aerobes, anaerobes, atypical mycobacterium, and fungi) were performed.
- There was no growth of any organisms on tissue culture.
- H&E showed features consistent with moderately differentiated SCC with high grade features.
- After discussion at tumor board, the patient was referred to radiation oncology, surgical oncology, and medical oncology for further management.
- The patient refused palliative radiation, but cemiplimab, a PD-1 inhibitor, is being initiated.

Discussion

- Cutaneous SCC is the second most common type of skin cancer with excellent outcomes after surgical removal in most cases.
- Local recurrence is rare, occurring in about 4.6% of tumors, but is a sign of aggressive biologic behavior.
- Clinical risk factors for recurrence/metastasis include:
- -Tumor diameter >2 cm
- -Immunosuppressed state
- -Location on the lip or ear
- -Arising in a burn or scar
- Histological risk factors for recurrence/metastasis on pathology include:
 - -Perineural invasion
- -Tumor depth with Breslow thickness > 2 mm (10x risk) -Poor differentiation (3x risk of well-differentiated)
- -Desmoplastic SCC subtype (10x risk of recurrence)
- In cases that recurrence of squamous cell carcinoma is a possibility, the threshold for biopsy is low even if the clinical course is not congruent.
- A multidisciplinary approach is critical in the management of these patients to reduce morbidity and mortality.
- Systemic therapies for advance SCC include:
 - -Chemotherapy (primarily platins)
 - -EGFR inhibitors
- -PD-1 inhibitors (cemiplimab, nivolumab, and pembrolizumab)
- Radiation continues to play a pivotal role in both curative and palliative treatment.

References

- Thompson AK, Kelley BF, Prokop LJ, et al. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: A systematic review and meta-analysis. JAMA dermatology. 2016;152(4):419-428.
- Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237-247.
- Ogata D, Tsuchida T. Systemic immunotherapy for advanced cutaneous squamous cell carcinoma. Curr Treat Options Oncol. 2019;20(4):30.

